An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?

References

• Taillibert S, Chamberlain MC. Leptomeningeal metastasis. In: Handbook of clinical neurology [internet]. Elsevier; 2018. p. 169–204. Available from: https://linkinghub.elsevier.com/retrieve/pii/B978012811161100013X
   Google Scholar
• Nguyen A, Nguyen A, Dada OT, et al. Leptomeningeal metastasis: a review of the pathophysiology, diagnostic methodology, and therapeutic Landscape. Current Oncol. MDPI 2023;30:5906–5931. doi: 10.3390/curroncol30060442
   PubMed Web of Science ®Google Scholar
• Clatot F, Philippin-Lauridant G, Ouvrier MJ, et al. Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy. J Neurooncol [Internet]. 2009;95(3):421–426. Available from. doi: 10.1007/s11060-009-9940-2
   PubMed Web of Science ®Google Scholar
• Mittica G, Senetta R, Richiardi L, et al. Meningeal carcinomatosis underdiagnosis and overestimation: incidence in a large consecutive and unselected population of breast cancer patients. BMC Cancer. 2015 Dec 29;15(1). doi: 10.1186/s12885-015-2042-y
   PubMedGoogle Scholar
• Le Rhun E, Taillibert S, Zairi F, et al. Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: a case-control study. J Neurooncol [Internet]. 2011;105(2):309–315. Available from. doi: 10.1007/s11060-011-0592-7
   PubMed Web of Science ®Google Scholar
• Lamba N, Cagney DN, Catalano PJ, et al. Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries. Neuro Oncol [Internet]. 2023;25(5):973–983. Available from. doi: 10.1093/neuonc/noac249
   PubMed Web of Science ®Google Scholar
• Pellerino A, Internò V, Mo F, et al. Management of brain and leptomeningeal metastases from breast cancer. Int J Mol Sci. 2020;21:1–26. MDPI AG. doi: 10.20517/2394-4722.2020.80
   Web of Science ®Google Scholar
• Abraham AA, Anoop TM, RJ P, et al. Clinical outcome of neoplastic meningitis associated with breast cancer. J Neurosci Rural Pract [Internet]. 2022;13:108–113. Available from: https://ruralneuropractice.com/clinical-outcome-of-neoplastic-meningitis-associated-with-breast-cancer/
   PubMed Web of Science ®Google Scholar
• Azevedo CRAS D, Cruz MRS, Chinen LTD, et al. Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neurooncol [Internet]. 2011;104(2):565–572. Available from: http://link.springer.com/10.1007/s11060-010-0524-y
   PubMed Web of Science ®Google Scholar
• Le Rhun E, Taillibert S, Chamberlain MC. Neoplastic meningitis due to Lung, breast, and Melanoma metastases. Cancer Control [Internet]. 2017;24(1):22–32. Available from. doi: 10.1177/107327481702400104
   PubMed Web of Science ®Google Scholar
• Lara-Medina F, Crismatt A, Villarreal-Garza C, et al. Clinical features and prognostic factors in patients with carcinomatous meningitis secondary to breast cancer. Breast J [Internet]. 2012 May 1;18(3):233–241. Available from. doi: 10.1111/j.1524-4741.2012.01228.x
   PubMed Web of Science ®Google Scholar
• Meattini I, Livi L, Saieva C, et al. Prognostic factors and clinical features in patients with leptomeningeal metastases from breast cancer: a single center experience. J Chemother [Internet]. 2012 Oct 1;24(5):279–284. Available from. doi: 10.1179/1973947812Y.0000000034
   PubMed Web of Science ®Google Scholar
• Niwińska A, Rudnicka H, Murawska M. Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival. Med Oncol [Internet]. 2013;30(1):408. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586398/
   PubMed Web of Science ®Google Scholar
• Le Rhun E, Taillibert S, Zairi F, et al. A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neurooncol [Internet]. 2013;113(1):83–92. Available from. doi: 10.1007/s11060-013-1092-8
   PubMed Web of Science ®Google Scholar
• Torrejón D, Oliveira M, Cortes J, et al. Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. Breast [Internet]. 2013;22(1):19–23. Available from: https://www.thebreastonline.com/article/S0960-9776(12)00210-X/fulltext
   PubMed Web of Science ®Google Scholar
• Kingston B, Kayhanian H, Brooks C, et al. Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: a single-centre experience. Breast. 2017 Dec 1;36:54–59. doi: 10.1016/j.breast.2017.07.015
   PubMed Web of Science ®Google Scholar
• Haddaway NR, Page MJ, Pritchard CC, et al. PRISMA2020: an R package and shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open Synthesis. Campbell Syst Rev [Internet]. 2022;18(2):e1230. Available from. doi: 10.1002/cl2.1230
   PubMed Web of Science ®Google Scholar
• Kunte S, Abraham J, Montero AJ. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer [Internet]. 2020;126(19):4278–4288. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32721042
   PubMed Web of Science ®Google Scholar
• Saura C, Oliveira M, YH F, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer Previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38(27):3138–3149. Available from
   PubMed Web of Science ®Google Scholar
• Schmidtova S, Kalavska K, Liskova V, et al. Targeting of deregulated Wnt/β-catenin signaling by PRI-724 and LGK974 inhibitors in germ cell tumor cell lines. Int J Mol Sci. 2021;22(8):4263. doi: 10.3390/ijms22084263
   PubMed Web of Science ®Google Scholar
• Aiyer R, Engelman E, Xue W, et al. Dysphagia and anorexia as presentations of leptomeningeal carcinomatosis. BMJ Case Rep [Internet]. 2016;2016:bcr2016214666. doi: 10.1136/bcr-2016-214666
   PubMedGoogle Scholar
• Fields MM. How to recognize and treat neoplastic meningitis. J Adv Pract Oncol [Internet]. 2013;4(3):155–160. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25031995
   PubMedGoogle Scholar
• Lukas RV, Mata-Machado NA, Nicholas MK, et al. Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature. Dis Esophagus [Internet]. 2015;28(8):772–781. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25142531
   PubMed Web of Science ®Google Scholar
• Hyun JW, Shin HS, Kim SH, et al. CYFRA 21-1 levels in cerebrospinal fluid as a putative therapeutic monitoring biomarker for patients with leptomeningeal carcinomatosis: a pilot study. Cancer Biomarkers. 2020;28(1):81–89. doi: 10.3233/CBM-190187
   PubMed Web of Science ®Google Scholar
• Assi HI, Mahmoud T, Saadeh FS, et al. Management of leptomeningeal metastasis in breast cancer. Clin Neurol Neurosur [Internet]. 2018;172:151–159. doi: 10.1016/j.clineuro.2018.07.001
   PubMed Web of Science ®Google Scholar
• Kondoh T, Sonoda T. Treatment options for leptomeningeal metastases of solid Cancers: literature review and personal experience. In: Chernov M, Hayashi M, Chen C McCutcheon I, editors. Gamma Knife Neurosurgery in the management of intracranial disorders II [internet]. Cham: Springer International Publishing; 2021. p. 71–84. Available from. doi: 10.1007/978-3-030-69217-9_8.
   Google Scholar
• Le Rhun E, Weller M, Brandsma D, et al. EANO–ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol [Internet]. 2017;28:iv84–99. Available from https://linkinghub.elsevier.com/retrieve/pii/S0923753419421492
   PubMed Web of Science ®Google Scholar
• Mokri B. Low cerebrospinal fluid pressure syndromes. Neurol Clin [Internet]. 2004;22(1):55–74, vi. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15062528
   PubMed Web of Science ®Google Scholar
• Moldovan TR, Căinap C, Fekete Z, et al. Signet ring cell gastric carcinoma with breast and leptomeningeal metastases: a case report. Med Pharm Rep. 2022;95(1):88–91. doi: 10.15386/mpr-1654
   PubMedGoogle Scholar
• Patterson JD, Farach AM, Singh M, et al. Leptomeningeal metastasis from neuroendocrine carcinoma of the cervix: illustrative case. J Neurosurg Case Less. 2023 Jan 1;5(5). doi: 10.3171/CASE22457
   PubMedGoogle Scholar
• Neeman E, Salamon N, Rettig M. Leptomeningeal carcinomatosis of prostate cancer: a case report and review of the literature. Rev Urol [Internet]. 2020;22(2):80–84. Available from. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393686/
   Google Scholar
• Jose N, Perla H, Iyadurai R, et al. Leptomeningeal carcinomatosis in a patient with gallbladder carcinoma. J Cytol. 2017 Apr 1;34(2):118–121. doi: 10.4103/0970-9371.203571
   PubMed Web of Science ®Google Scholar
• Kim HR, Jo H, Kim H, et al. Osimertinib combined with systemic chemotherapy for EGFR mutant, T790M-Negative, non-small cell Lung cancer patients who develop leptomeningeal metastases with extracranial progression to prior EGFR TKI. Cancer Res Treat [Internet]. 2023;55(1):344–349. Available from: https://files/4170/Kim.et.al.2023-Osimertinib_Combined–with-Systemic.Chemotherapy.fo.pdf
   PubMed Web of Science ®Google Scholar
• Wang X, Cai J, Zeng Z, et al. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study. BMC Cancer. 2021 Dec 1;21(1). doi: 10.1186/s12885-021-08581-2
   Web of Science ®Google Scholar
• Anwar A, Gudlavalleti A, Ramadas P. Carcinomatous meningitis. In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from:http://www.ncbi.nlm.nih.gov/books/NBK560816/
   Google Scholar
• Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false- negative results. Cancer. 1998 Feb 15;82(4):733–739. doi: 10.1002/(SICI)1097-0142(19980215)82:4<733:AID-CNCR17>3.0.CO;2-Z
   PubMed Web of Science ®Google Scholar
• Nayar G, Ejikeme T, Chongsathidkiet P, et al. Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget [Internet]. 2017;8(42):73312–73328. Available from: http://files/4143/Nayar.et.al-2017- Leptomeningeal-disease-current-diagnostic-and-the.pdf
   PubMedGoogle Scholar
• Pellerino A, Bertero L, Rudà R, et al. Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. Ther Adv Neurol Disord [Internet]. 2018;11:1756286418759618. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844521/
   Web of Science ®Google Scholar
• Niwińska A, Rudnicka H, Murawska M. Breast cancer leptomeningeal metastasis: the results of combined treatment and the comparison of methotrexate and liposomal cytarabine as intra-cerebrospinal fluid chemotherapy. Clin Breast Cancer [Internet]. 2015;15(1):66–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25287959
   PubMed Web of Science ®Google Scholar
• Pan Z, Yang G, He H, et al. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: a prospective and single-arm study. Int J Cancer. 2016 Oct 15;139(8):1864–1872. doi: 10.1002/ijc.30214
   PubMed Web of Science ®Google Scholar
• Ahmed M, Begum T, Omer AR, et al. Leptomeningeal carcinomatosis from oesophageal cancer, presenting as meningitis. BMJ Case Rep [Internet]. 2016;2016:bcr2015210974. Available from: http://files/4190/Ahmed.et.al-2016-Leptomeningeal.carcinomatosis.from.oesophageal.can.pdf
   PubMedGoogle Scholar
• Takahashi H, Isogawa M. Management of breast cancer brain metastases. Chin Clin Oncol [Internet]. 2018;7(3):30. doi: 10.21037/cco.2018.05.06
   PubMedGoogle Scholar
• Mix M, Elmarzouky R, O’Connor T, et al. Clinical outcomes in patients with brain metastases from breast cancer treated with single-session radiosurgery or whole brain radiotherapy. J Neurosurg [Internet]. 2016;125(Suppl 1):26–30. Available from: http://files/4195/Mix.et.al-2016-Clinical.outcomes.in.patients.with.brain.metastase.pdf
   PubMedGoogle Scholar
• Mollica L, Leli C, Puglisi S, et al. Leptomeningeal carcinomatosis and breast cancer: a systematic review of current evidence on diagnosis, treatment and prognosis. Drugs Context [Internet]. 2021;10:2021-6–6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552906/
   Google Scholar
• Gill CM, Brastianos PK. Management of leptomeningeal carcinomatosis and challenges of trial design. Curr Opin Oncol [Internet]. 2019;31(6):508–513. Available from. doi: 10.1097/CCO.0000000000000574
   PubMed Web of Science ®Google Scholar
• Le Rhun E, Preusser M, van den Bent M, et al. How we treat patients with leptomeningeal metastases. ESMO Open [Internet]. 2019;4(Suppl 2):e000507. Available from: https://europepmc.org/articles/pmc6555600?pdf=render
   PubMedGoogle Scholar
• Bonneau C, Paintaud G, Trédan O, et al. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur J Cancer [Internet]. 2018;95:75–84. doi: 10.1016/j.ejca.2018.02.032
   PubMed Web of Science ®Google Scholar
• Kosmas C, Malamos NA, Tsavaris NB, et al. Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer. Oncology. 2002;63(1):6–15. doi: 10.1159/000065714
   PubMed Web of Science ®Google Scholar
• Ursu R, Taillibert S, Banissi C, et al. Immunotherapy with CpG-ODN in neoplastic meningitis: a phase I trial. Cancer Sci. 2015 Sep;106(9):1212–1218. doi: 10.1111/cas.12724
   PubMed Web of Science ®Google Scholar
• Bernardi RJ, Bomgaars L, Fox E, et al. Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol. 2008 Jul;62(2):355–361. doi: 10.1007/s00280-007-0601-x
   PubMed Web of Science ®Google Scholar
• Le Rhun E, Taillibert S, Zairi F, et al. Prolonged survival of patients with breast cancer-related leptomeningeal metastases. Anticancer Res. 2013 May;33(5):2057–2063.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Khatibi S, Kim JC, et al. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol. 1993 Mar;50(3):261–264. doi: 10.1001/archneur.1993.00540030027009
   PubMed Web of Science ®Google Scholar
• Le Rhun E, Wallet J, Mailliez A, et al. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. Neuro Oncol [Internet]. 2020;22(4):524–538. doi: 10.1093/neuonc/noz201
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Phuphanich S, van den BM, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer [Internet]. 2001;84(2):157–163. Available from: https://www.nature.com/articles/6691574
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999 Nov;5(11):3394–3402.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Tsao-Wei DD, Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer. 2006 May 1;106(9):2021–2027. doi: 10.1002/cncr.21828
   PubMed Web of Science ®Google Scholar
• Cole BF, Glantz MJ, Jaeckle KA, et al. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer. 2003 Jun 15;97(12):3053–3060. doi: 10.1002/cncr.11449
   PubMed Web of Science ®Google Scholar
• Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology group. Available from J Clin Oncol [Internet]. 1993;11(3):561–569. doi: 10.1200/JCO.1993.11.3.561
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Batchelor T, O’Day SJ, et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol. 2002 May;57(3):231–239. doi: 10.1023/A:1015752331041
   PubMed Web of Science ®Google Scholar
• Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer. 2004 Dec;40(18):2726–2733. doi: 10.1016/j.ejca.2004.08.012
   PubMed Web of Science ®Google Scholar
• Groves MD, Glantz MJ, Chamberlain MC, et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 2008 Apr;10(2):208–215. doi: 10.1215/15228517-2007-059
   PubMed Web of Science ®Google Scholar
• Blaney SM, Heideman R, Berg S, et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003 Jan 1;21(1):143–147. doi: 10.1200/JCO.2003.04.053
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Miyahara E, Suzuki T, et al. Continuous intrathecal administration of 5-fluoro-2’-deoxyuridine for the treatment of neoplastic meningitis. Neurosurgery. 2005 Aug;57(2):266–280. doi: 10.1227/01.NEU.0000166543.45294.F6. discussion 266-80.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer. 2002 May 15;94(10):2675–2680. doi: 10.1002/cncr.10547
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Van Horn A, Fisher R, et al. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer. 2010 Apr 15;116(8):1947–1952. doi: 10.1002/cncr.24921
   PubMed Web of Science ®Google Scholar
• Murthy RK, O’Brien B, Berry DA, et al. Abstract PD4-02: safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: results from TBCRC049, a phase 2 non-randomized study. Cancer Res. 2022 Feb 15;82(4_Supplement):D4-02-PD4–02. doi: 10.1158/1538-7445.SABCS21-PD4-02
   Web of Science ®Google Scholar
• Peereboom DM, Murphy C, Ahluwalia MS, et al. Phase II trial of patupilone in patients with brain metastases from breast cancer. Neuro Oncol. 2014 Apr 1;16(4):579–583. doi: 10.1093/neuonc/not305
   PubMed Web of Science ®Google Scholar
• Morikawa A, de Stanchina E, Pentsova E, et al. Phase I study of Intermittent high-dose lapatinib alternating with capecitabine for HER2-positive breast cancer patients with central nervous system metastases. Clin Cancer Res [Internet]. 2019;25(13):3784–3792. doi: 10.1158/1078-0432.CCR-18-3502
   PubMed Web of Science ®Google Scholar
• Pérez-García JM, Vaz Batista M, Cortez P, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol. 2023 Jan 5;25(1):157–166. doi: 10.1093/neuonc/noac144
   PubMed Web of Science ®Google Scholar
• Brastianos PK, Strickland MR, Lee EQ, et al. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat Commun. 2021 Oct 12;12(1):5954. doi: 10.1038/s41467-021-25859-y
   PubMed Web of Science ®Google Scholar
• Kumthekar P, Tang SC, Brenner AJ, et al. ANG1005, a brain-penetrating peptide–drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases. Clin Cancer Res [Internet]. 2020;26(12):2789–2799. Available from. doi: 10.1158/1078-0432.CCR-19-3258
   PubMed Web of Science ®Google Scholar
• Brastianos PK, Lee EQ, V CJ, et al. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020;26(8):1280–1284. doi: 10.1038/s41591-020-0918-0
   PubMed Web of Science ®Google Scholar
• Wu PF, Lin CH, Kuo CH, et al. A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis. BMC Cancer. 2015 Apr 17;15(1):299. doi: 10.1186/s12885-015-1290-1
   PubMedGoogle Scholar
• Mrugala MM, Kim B, Sharma A, et al. Phase II study of systemic high-dose methotrexate and intrathecal liposomal cytarabine for treatment of leptomeningeal carcinomatosis from breast cancer. Clin Breast Cancer. 2019 Oct;19(5):311–316. doi: 10.1016/j.clbc.2019.04.004
   PubMed Web of Science ®Google Scholar
• Rudnicka H, Niwińska A, Murawska M. Breast cancer leptomeningeal metastasis–the role of multimodality treatment. J Neurooncol [Internet]. 2007;84(1):57–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17310266
   PubMed Web of Science ®Google Scholar
• Ekenel M, Hormigo AM, Peak S, et al. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol [Internet]. 2007;85(2):223–227. doi: 10.1007/s11060-007-9409-0
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol [Internet]. 1998 Apr 1;16(4): 1561–1567. Available from. 10.1200/JCO.1998.16.4.1561.
   PubMed Web of Science ®Google Scholar
• Tetef ML, Margolin KA, Doroshow JH, et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol [Internet]. 2000;46(1):19–26. doi: 10.1007/s002800000118
   PubMed Web of Science ®Google Scholar
• Freilich RJ, Seidman AD, DeAngelis LM. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer. 1995 Jul 15;76(2):232–236. doi: 10.1002/1097-0142(19950715)76:2<232:AID-CNCR2820760212>3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. Surg Neurol Int [Internet]. 2013;4(Suppl 4):S265–88. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656567/
   PubMedGoogle Scholar
• Pfeffer MR, Wygoda M, Siegal T. Leptomeningeal metastases–treatment results in 98 consecutive patients. Isr J Med Sci [Internet]. 1988;24(9–10):611–618. Available from. http://www.ncbi.nlm.nih.gov/pubmed/3144516
   Google Scholar
• Prospective evaluation of high-dose systemic methotrexate in patients with breast cancer and leptomeningeal metastasis - full text view - ClinicalTrials.Gov [Internet]. [cited 2023 Nov 14]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT02422641
   Google Scholar
• Howard SC, McCormick J, Pui CH, et al. Preventing and managing toxicities of high-dose methotrexate. Oncology [Internet]. 2016;21(12):1471–1482. doi: 10.1634/theoncologist.2015-0164
   PubMed Web of Science ®Google Scholar
• Al-Quteimat OM, Al-Badaineh MA. Practical issues with high dose methotrexate therapy. Saudi Pharm J [Internet]. 2014;22(4):385–387. doi: 10.1016/j.jsps.2014.03.002
   PubMed Web of Science ®Google Scholar
• Giglio P, Tremont-Lukats IW, Groves MD. Response of neoplastic meningitis from solid tumors to oral capecitabine. Available from J Neurooncol [Internet]. 2003;65(2):167–172. doi: 10.1023/B:NEON.0000003752.89814.ca
   PubMed Web of Science ®Google Scholar
• Tham YL, Hinckley L, Teh BS, et al. Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer [Internet]. 2006 Jun 1;7(2):164–166. Available from. doi: 10.3816/CBC.2006.n.028
   PubMed Web of Science ®Google Scholar
• Onishi H, Morisaki T, Nakafusa Y, et al. Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. Int J Clin Oncol [Internet]. 2011;16(6):718–721. Available from. doi: 10.1007/s10147-011-0195-5
   PubMed Web of Science ®Google Scholar
• Platini C. Trastuzumab and blood-brain barrier. Bull Cancer. 2007 Oct;94(10):857–859.
   PubMed Web of Science ®Google Scholar
• Robins HI, Liu G, Hayes L, et al. Trastuzumab for breast cancer-related carcinomatous meningitis. Clin Breast Cancer [Internet]. 2002;2(4):316. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11899365
   PubMedGoogle Scholar
• Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol [Internet]. 2000;18(11):2349–2351. doi: 10.1200/JCO.2000.18.11.2349
   PubMed Web of Science ®Google Scholar
• Stemmler HJ, Schmitt M, Willems A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier. Anticancer Drugs [Internet]. 2007;18(1):23. Available from: https://journals.lww.com/anti-cancerdrugs/abstract/2007/01000/ratio_of_trastuzumab_levels_in_serum_and.4.aspx
   PubMed Web of Science ®Google Scholar
• Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther [Internet]. 2010;87(5):586–592. doi: 10.1038/clpt.2010.12
   PubMed Web of Science ®Google Scholar
• Le Tilly O, Azzopardi N, Bonneau C, et al. Antigen Mass may influence trastuzumab concentrations in cerebrospinal fluid after intrathecal administration. Clin Pharmacol Ther. 2021 Jul;110(1):210–219. doi: 10.1002/cpt.2188
   PubMed Web of Science ®Google Scholar
• Lazaratos AM, Maritan SM, Quaiattini A, et al. Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases. Breast. Churchill Livingstone 2023;69:451–468. doi: 10.1016/j.breast.2023.04.008
   PubMed Web of Science ®Google Scholar
• Shigekawa T, Takeuchi H, Misumi M, et al. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. Breast Cancer [Internet]. 2009;16(1):88–92. Available from. doi: 10.1007/s12282-008-0056-x
   PubMed Web of Science ®Google Scholar
• Ricciardi GRR, Russo A, Franchina T, et al. Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review. BMC Cancer. 2018 Jan 25;18(1). doi: 10.1186/s12885-018-3994-5
   PubMedGoogle Scholar
• Junttila TT, Li G, Parsons K, et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat [Internet]. 2011;128(2):347–356. doi: 10.1007/s10549-010-1090-x
   PubMed Web of Science ®Google Scholar
• Krop IE, Lin NU, Blackwell K, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015 Jan 1;26(1):113–119. doi: 10.1093/annonc/mdu486
   PubMed Web of Science ®Google Scholar
• Montemurro F, Delaloge S, Barrios CH, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆. Ann Oncol. 2020 Oct 1;31(10):1350–1358. doi: 10.1016/j.annonc.2020.06.020
   PubMed Web of Science ®Google Scholar
• Alder L, Trapani D, Bradbury C, et al. Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. NPJ Breast Cancer [Internet]. 2023;91:1–5. https://www.nature.com/articles/s41523-023-00519-0.
   PubMed Web of Science ®Google Scholar
• Niikura N, Yamanaka T, Nomura H, et al. Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM). NPJ Breast Cancer. 2023 Dec 1;9(1). doi: 10.1038/s41523-023-00584-5
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Pegram MD, Tan-Chiu E, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol [Internet]. 2009;20(6):1026–1031. doi: 10.1093/annonc/mdn759
   PubMed Web of Science ®Google Scholar
• Sirhan Z, Thyagarajan A, Sahu RP. The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer. Mil Med Res [Internet]. 2022;9(1):39. doi: 10.1186/s40779-022-00401-3
   Google Scholar
• Morikawa A, de Stanchina E, Pentsova E, et al. Phase I study of Intermittent high-dose lapatinib alternating with capecitabine for HER2-positive breast cancer patients with central nervous system metastases. Clin Cancer Res [Internet]. 2019;25(13):3784–3792. Available from: http://files/4216/Morikawa.et.al-2019-Phase.I.Study.of.Intermittent.High-Dose.Lapatinib.pdf
   PubMed Web of Science ®Google Scholar
• Lin NU, Diéras V, Paul D, et al. Multicenter Phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res [Internet]. 2009;15(4):1452–1459. Available from. doi: 10.1158/1078-0432.CCR-08-1080
   PubMed Web of Science ®Google Scholar
• Pellerino A, Soffietti R, Bruno F, et al. Neratinib and capecitabine for the treatment of leptomeningeal metastases from HER2-positive breast cancer: a series in the setting of a compassionate program. Cancers (Basel). 2022 Mar 1;14(5):1192. doi: 10.3390/cancers14051192
   PubMed Web of Science ®Google Scholar
• Murthy R, O’Brien B, Berry D, et al. Abstract D4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study. Cancer Research. 2022;82(4_Supplement):PD4–02. Available from: https://www.researchgate.net/publication/367772881_Abstract_PD4-02_Safety_and_efficacy_of_a_tucatinib-trastuzumab-capecitabine_regimen_for_treatment_of_leptomeningeal_metastasis_LM_in_HER2-positive_breast_cancer_Results_from_TBCRC049_a_phase_2_non-ran
   Web of Science ®Google Scholar
• Stemmler HJ, Mengele K, Schmitt M, et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs. 2008 Sep;19(8):832–836. doi: 10.1097/CAD.0b013e32830b58b0
   PubMed Web of Science ®Google Scholar
• Rogers LR, Remer SE, Tejwani S. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neuro Oncol [Internet]. 2004;6(1):63–64. doi: 10.1215/S1152851703000334
   PubMed Web of Science ®Google Scholar
• Meireles S, Costa A, Salgado M, et al. A case report of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy. Breast [Internet]. 2011;20:S49. Available from: https://www.thebreastonline.com/article/S0960-9776(11)00274-8/fulltext
   Web of Science ®Google Scholar
• Poplack DG, Horowitz ME, Bleyer WA. Pharmacology of antineoplastic agents in cerebrospinal fluid. In: Wood J, editor. Neurobiology of cerebrospinal fluid 1 [internet]. Boston MA: Springer US; 1980. p. 561–578. Available from. doi: 10.1007/978-1-4684-1039-6_39.
   Google Scholar
• Gauthier H, Guilhaume MN, Bidard FC, et al. Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol [Internet]. 2010;21(11):2183–2187. Available from: https://www.annalsofoncology.org/article/S0923-7534(19)39543-2/fulltext
   PubMed Web of Science ®Google Scholar
• Jayson GC, Howell A, Harris M, et al. Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer. 1994;74(12):3135–3141. Available from. doi: 10.1002/1097-0142(19941215)74:12<3135:AID-CNCR2820741212>3.0.CO;2-8
   PubMed Web of Science ®Google Scholar
• Carausu M, Carton M, Darlix A, et al. Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database. ESMO Open [Internet]. 2021;6(3):100150. doi: 10.1016/j.esmoop.2021.100150
   PubMed Web of Science ®Google Scholar
• Pan Z, Yang G, Yuan T, et al. Leptomeningeal metastasis from hepatocellular carcinoma with other unusual metastases: a case report. BMC Cancer. 2014 Jun 2;14(1). doi: 10.1186/1471-2407-14-399
   Google Scholar
• Drachtman RA, Cole PD, Golden CB, et al. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol [Internet]. 2002;19(5):319–327. doi: 10.1080/08880010290057336
   PubMed Web of Science ®Google Scholar
• Le Rhun E, Taillibert S, Zairi F, et al. Prolonged survival of patients with breast cancer-related leptomeningeal metastases. Anticancer Res [Internet]. 2013;33(5):2057–2063. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23645756
   PubMed Web of Science ®Google Scholar
• Laakmann E, Witzel I, Müller V. Efficacy of liposomal cytarabine in the treatment of leptomeningeal metastasis of breast cancer. Breast Care. 2017 Jul 1;12(3):165–167. doi: 10.1159/000464400
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Soh LT, Holmes FA, et al. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol [Internet]. 2000;46(5):382–386. Available from. doi: 10.1007/s002800000173
   PubMed Web of Science ®Google Scholar
• Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of Lymphomatous meningitis. J Clin Oncol [Internet]. 1999;17(10):3110–3116. Available from. doi: 10.1200/JCO.1999.17.10.3110
   PubMed Web of Science ®Google Scholar
• Gaviani P, Corsini E, Salmaggi A, et al. Liposomal cytarabine in neoplastic meningitis from primary brain tumors: a single institutional experience. Neurol Sci. 2013 Dec;34(12):2151–2157. doi: 10.1007/s10072-013-1358-0
   PubMed Web of Science ®Google Scholar
• Ostermann K, Pels H, Kowoll A, et al. Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. J Neurooncol [Internet]. 2011;103(3):635–640. doi: 10.1007/s11060-010-0435-y
   PubMed Web of Science ®Google Scholar
• Jahn F, Jordan K, Behlendorf T, et al. Safety and efficacy of liposomal cytarabine in the treatment of neoplastic meningitis. Oncology [Internet]. 2015;89(3):137–142. doi: 10.1159/000380913
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res [Internet]. 1999;5(11):3394–3402. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10589750
   PubMed Web of Science ®Google Scholar
• Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol [Internet]. 1987;5(10):1655–1662. doi: 10.1200/JCO.1987.5.10.1655
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J Neurooncol. 2012 Aug;109(1):143–148. doi: 10.1007/s11060-012-0880-x
   PubMed Web of Science ®Google Scholar
• Huitema ADR, Matho RAA, Tibben MM, et al. Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy. Br J Clin Pharmacol. 2001;51(1):61–70. doi: 10.1046/j.1365-2125.2001.01301.x
   PubMed Web of Science ®Google Scholar
• Ferrario C, Davidson A, Bouganim N, et al. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol [Internet]. 2009;20(4):792–795. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753419407254
   PubMed Web of Science ®Google Scholar
• Gutin PH, Weiss HD, Wiernik PH, et al. N-triethylenethiophosphoramide [thio-TEPA (NSC 6396)] in the treatment of malignant meningeal disease: phase I-II study. Cancer. 1976 Oct;38(4):1471–1475.
   PubMed Web of Science ®Google Scholar
• Strong JM, Collins JM, Lester C, et al. Pharmacokinetics of intraventricular and intravenous N,N’,N”-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res. 1986 Dec;46(12 Pt 1):6101–6104.
   PubMed Web of Science ®Google Scholar
• Comte A, Jdid W, Guilhaume MN, et al. Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa. J Neurooncol [Internet]. 2013;115(3):445–452. Available from: http://link.springer.com/10.1007/s11060-013-1244-x
   PubMed Web of Science ®Google Scholar
• Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology group. Available from J Clin Oncology [Internet]. 1993;11(3):561–569. doi: 10.1200/JCO.1993.11.3.561
   PubMed Web of Science ®Google Scholar
• Walker JG, Schultz DL, Grisdale KA, et al. Case studies of patients receiving intraventricular topotecan for treatment of neoplastic meningitis. J Clin Oncol [Internet]. 2010;28(15_suppl):e12540–e12540. Available from. doi: 10.1200/jco.2010.28.15_suppl.e12540
   Web of Science ®Google Scholar
• Blaney SM, Cole DE, Godwin K, et al. Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol [Internet]. 1995;36(2):121–124. Available from. doi: 10.1007/BF00689195
   PubMed Web of Science ®Google Scholar
• Blaney SM, Heideman R, Berg S, et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol [Internet]. 2003;21(1):143–147. Available from. doi: 10.1200/JCO.2003.04.053
   PubMed Web of Science ®Google Scholar
• Groves MD, Glantz MJ, Chamberlain MC, et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol [Internet]. 2008;10(2):208–215. doi: 10.1215/15228517-2007-059
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Dixon JG, Anderson SK, et al. Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases. Cancer Med [Internet]. 2020;9(21):7935–7942. doi: 10.1002/cam4.3422
   PubMed Web of Science ®Google Scholar
• Park WY, Kim HJ, Kim K, et al. Intrathecal trastuzumab treatment in patients with breast cancer and Leptomeningeal Carcinomatosis. Cancer Res Treat [Internet]. 2016;48(2):843–847. doi: 10.4143/crt.2014.234
   PubMed Web of Science ®Google Scholar
• Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol [Internet]. 2006;7(9):778–780. doi: 10.1016/S1470-2045(06)70864-6
   PubMed Web of Science ®Google Scholar
• Pluchart H, Jacquet E, Charlety D, et al. Long-term survivor with intrathecal and intravenous trastuzumab treatment in metastatic breast cancer. Target Oncol [Internet]. 2016;11(5):687–691. doi: 10.1007/s11523-016-0429-6
   PubMed Web of Science ®Google Scholar
• Mego M, Sycova-Mila Z, Obertova J, et al. Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis. Breast [Internet]. 2011;20(5):478–480. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0960977611001238
   PubMed Web of Science ®Google Scholar
• Allison DL, Glantz M, Werner TL, et al. Intra-CSF trastuzumab in patients with neoplastic meningitis from breast cancer or primary brain tumors. J Clin Oncol [Internet]. 2009;27(15_suppl):2066. Available from. doi: 10.1200/jco.2009.27.15_suppl.2066
   PubMed Web of Science ®Google Scholar
• Bonneau C, Paintaud G, Trédan O, et al. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur J Cancer [Internet]. 2018;95:75–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29635147
   PubMed Web of Science ®Google Scholar
• Oberkampf F, Gutierrez M, Trabelsi Grati O, et al. Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis. Neuro Oncol [Internet]. 2023;25(2):365–374. doi: 10.1093/neuonc/noac180
   PubMed Web of Science ®Google Scholar
• Kumthekar PU, Avram MJ, Lassman AB, et al. A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro Oncol. 2023 Mar 14;25(3):557–565. doi: 10.1093/neuonc/noac195
   PubMed Web of Science ®Google Scholar
• Zagouri F, Zoumpourlis P, Le Rhun E, et al. Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: a metanalysis with meta-regression. Cancer Treat Rev. 2020 Aug;88:102046.
   PubMed Web of Science ®Google Scholar
• Larson SM, Schall GL, Di Chiro G. The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography. J Nucl Med [Internet]. 1971;12(8):555–557. Available from. http://www.ncbi.nlm.nih.gov/pubmed/5093427
   Google Scholar
• Hudgins PA, Fountain AJ, Chapman PR, et al. Difficult lumbar puncture: pitfalls and tips from the trenches. AJNR Am J Neuroradiol. 2017;38(7):1276–1283. doi: 10.3174/ajnr.A5128
   PubMed Web of Science ®Google Scholar
• Nguyen TK, Nguyen EK, Soliman H. An overview of leptomeningeal disease. Ann Palliat Med. 2021;10:909–922. AME Publishing Company. doi: 10.21037/apm-20-973.
   PubMed Web of Science ®Google Scholar
• Johnson WR, Theeler BJ, Van Echo D, et al. Treatment of Leptomeningeal Carcinomatosis in a patient with metastatic pancreatic cancer: a case report and review of the literature. Case Rep Oncol. 2018;11(2):281–288. doi: 10.1159/000489085
   PubMedGoogle Scholar
• Li H, Zheng S, Lin Y, et al. Safety, pharmacokinetic and clinical activity of intrathecal chemotherapy with Pemetrexed via the Ommaya reservoir for leptomeningeal metastases from Lung adenocarcinoma: a prospective Phase I study. Clin Lung Cancer. 2023 Mar;24(2):e94–104. doi: 10.1016/j.cllc.2022.11.011
   PubMed Web of Science ®Google Scholar
• Roth P, Weller M. Management of neoplastic meningitis. Chin Clin Oncol [Internet]. 2015;4(2):26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26112812
   PubMedGoogle Scholar
• Wang B, Guo H, Xu H, et al. Research Progress and Challenges in the treatment of central nervous system metastasis of non-small cell Lung cancer. Cells. 2021;10(10):2620. Available from: http://files/4289/Wang.et.al-2021-Research.Progress.and.Challenges.in.the.Treatment.pdf
   PubMed Web of Science ®Google Scholar
• Bartolotti M, Franceschi E, Brandes AA. Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. Future Oncol. 2013 Nov;9(11):1653–1664. doi: 10.2217/fon.13.90
   PubMed Web of Science ®Google Scholar
• Willett A, Wilkinson JB, Shah C, et al. Management of solitary and multiple brain metastases from breast cancer. Indian J Med Paediatr Oncol. 2015;36(2):87–93. doi: 10.4103/0971-5851.158835
   PubMedGoogle Scholar
• Mampre D, Mehkri Y, Rajkumar S, et al. Treatment of breast cancer brain metastases: radiotherapy and emerging preclinical approaches. Diagn Ther. 2022;1(1):25–38. doi: 10.55976/dt.1202216523-36
   Google Scholar
• Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014 Apr;15(4):387–395. doi: 10.1016/S1470-2045(14)70061-0
   PubMed Web of Science ®Google Scholar
• Brown PD, V BK, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1049–1060. doi: 10.1016/S1470-2045(17)30441-2
   PubMed Web of Science ®Google Scholar
• Hirano Y, Konishi K, Ejima Y. Utility of whole brain radiation therapy for leptomeningeal carcinomatosis. Int J Clin Oncol [Internet]. 2020;25(7):1432–1439. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32274614
   PubMed Web of Science ®Google Scholar
• Proton Craniospinal Irradiation for Leptomeningeal Metastasis. ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT05746754
   Google Scholar
• Proton Craniospinal Radiation Therapy vs. Partial photon radiation therapy for leptomeningeal metastasis from solid tumors. ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT04343573
   Google Scholar
• Yang JT, Wijetunga NA, Pentsova E, et al. Randomized Phase II trial of proton craniospinal irradiation versus photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis. J Clin Oncol [Internet]. 2022;40(33):3858–3867. doi: 10.1200/JCO.22.01148
   PubMed Web of Science ®Google Scholar
• Yang TJ, Wijetunga NA, Yamada J, et al. Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. Neuro Oncol [Internet]. 2021;23(1):134–143. Available from. doi: 10.1093/neuonc/noaa152
   PubMed Web of Science ®Google Scholar
• Radiation therapy followed by intrathecal trastuzumab/pertuzumab in HER2+ breast leptomeningeal disease. ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT04588545
   Google Scholar
• Pellerino A, Brastianos PK, Rudà R, et al. Leptomeningeal metastases from solid tumors: recent advances in diagnosis and molecular approaches. Cancers (Basel). 2021 Jun 9;13(12):2888. doi: 10.3390/cancers13122888
   PubMed Web of Science ®Google Scholar
• Dudani S, Mazzarello S, Hilton J, et al. Optimal management of leptomeningeal carcinomatosis in breast cancer patients-A systematic review. Clin Breast Cancer [Internet]. 2016;16(6):456–470. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27553811
   PubMed Web of Science ®Google Scholar
• Wang N, Bertalan MS, Brastianos PK. Leptomeningeal metastasis from systemic cancer: review and update on management. Cancer. 2018 Jan 1;124(1):21–35. doi: 10.1002/cncr.30911
   PubMed Web of Science ®Google Scholar
• Horbinski C, Nabors LB, Portnow J, et al. NCCN guidelines® insights: central nervous system Cancers, version 2.2022. J Natl Compr Canc Netw. 2023 Jan;21(1):12–20. doi: 10.6004/jnccn.2023.0002
   PubMed Web of Science ®Google Scholar
• Franzoi MA, Hortobagyi GN. Leptomeningeal carcinomatosis in patients with breast cancer. Crit Rev Oncol Hematol [Internet]. 2019;135:85–94. doi: 10.1016/j.critrevonc.2019.01.020
   PubMed Web of Science ®Google Scholar
• Mack F, Baumert BG, Schäfer N, et al. Therapy of leptomeningeal metastasis in solid tumors. Cancer Treat Rev [Internet]. 2016;43:83–91. doi: 10.1016/j.ctrv.2015.12.004
   PubMed Web of Science ®Google Scholar
• Le Rhun E, Rudà R, Devos P, et al. Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. J Neurooncol [Internet]. 2017;133(2):419–427. Available from: https://www.zora.uzh.ch/id/eprint/141051/1/Sammelmappe2.pdf
   PubMed Web of Science ®Google Scholar
• Tripathy S, Ahmad SR. Raised intracranial pressure syndrome: a stepwise approach. Indian J Crit Care Med [Internet]. 2019;23(Suppl 2):S129–35. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707500/
   PubMedGoogle Scholar
• Khosla AA, Saxena S, Ozair A, et al. Novel therapeutic approaches in neoplastic meningitis. Cancers (Basel) [Internet]. 2022;15(1):119. Available from. doi: 10.3390/cancers15010119
   PubMed Web of Science ®Google Scholar
• Kim HS, Park JB, Gwak HS, et al. Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis. World J Surg Oncol [Internet]. 2019;17(1):59. Available from. doi: 10.1186/s12957-019-1595-7
   PubMedGoogle Scholar
• SSafety and efficacy study of PRI-724 in subjects with advanced solid tumors. ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT01302405
   Google Scholar
• A study of LGK974 in patients with malignancies dependent on Wnt ligands. ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT01351103
   Google Scholar
• Richter S, Bedard PL, Chen EX, et al. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Invest New Drugs. 2014;32(2):243–249. doi: 10.1007/s10637-013-9965-4
   PubMed Web of Science ®Google Scholar
• Dattilo R, Mottini C, Camera E, et al. Pyrvinium pamoate induces death of triple-negative breast cancer stem-like cells and reduces metastases through effects on lipid anabolism. Cancer Res. 2020 Oct 1;80(19):4087–4102. doi: 10.1158/0008-5472.CAN-19-1184
   PubMed Web of Science ®Google Scholar
• Plimack ER, LoRusso PM, McCoon P, et al. AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncology. 2013;18(7):819–820. doi: 10.1634/theoncologist.2013-0198
   Google Scholar
• Garrido-Castro AC, Saura C, Barroso-Sousa R, et al. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2020;22(1):120. doi: 10.1186/s13058-020-01354-y
   PubMed Web of Science ®Google Scholar
• Martín M, Chan A, Dirix L, et al. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4). Ann Oncol. 2017;28(2):313–320. doi: 10.1093/annonc/mdw562
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–529. doi: 10.1056/NEJMoa1109653
   PubMed Web of Science ®Google Scholar
• Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012 Aug 1;30(22):2718–2724. doi: 10.1200/JCO.2011.39.0708
   PubMed Web of Science ®Google Scholar
• Massarweh S, Romond E, Black EP, et al. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure. Breast Cancer Res Treat. 2014;143(2):325–332. doi: 10.1007/s10549-013-2810-9
   PubMed Web of Science ®Google Scholar
• André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–1940. doi: 10.1056/NEJMoa1813904
   PubMed Web of Science ®Google Scholar
• Sarker D, Ang JE, Baird R, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan–class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(1):77–86. doi: 10.1158/1078-0432.CCR-14-0947
   PubMed Web of Science ®Google Scholar
• Schöffski P, Cresta S, Mayer IA, et al. A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Res. 2018;20(1):1–12. doi: 10.1186/s13058-018-1015-x
   PubMedGoogle Scholar
• Winer EP, Lipatov O, Im SA, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):499–511. doi: 10.1016/S1470-2045(20)30754-3
   PubMed Web of Science ®Google Scholar
• Chia S, Bedard PL, Hilton J, et al. A phase ib trial of durvalumab in combination with trastuzumab in HER2‐positive metastatic breast cancer (CCTG IND.229). Oncology. 2019;24(11):1439–1445. doi: 10.1634/theoncologist.2019-0321
   Google Scholar
• Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018 Feb;167(3):671–686. doi: 10.1007/s10549-017-4537-5
   PubMed Web of Science ®Google Scholar
• Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021 Aug;32(8):983–993. doi: 10.1016/j.annonc.2021.05.355
   PubMed Web of Science ®Google Scholar
• Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994–1004. doi: 10.1016/j.annonc.2021.05.801
   PubMed Web of Science ®Google Scholar
• Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020 Oct;21(10):1283–1295. doi: 10.1016/S1470-2045(20)30465-4
   PubMed Web of Science ®Google Scholar
• Huober J, Barrios CH, Niikura N, et al. Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer: primary results of the randomized Phase III IMpassion050 trial. J Clin Oncol. 2022 Sep 1;40(25):2946–2956. doi: 10.1200/JCO.21.02772
   PubMed Web of Science ®Google Scholar
• HER2-CAR T cells in treating patients with recurrent brain or leptomeningeal metastases. ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT03696030
   Google Scholar
• Safety and activity study of HER2-targeted dual switch CAR-T cells (BPX-603) in subjects with HER2-positive solid tumors. ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT04650451
   Google Scholar
• Autologous huMNC2-CAR44 or huMNC2-CAR22 T cells for breast cancer targeting cleaved form of MUC1 (MUC1*) ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT04020575
   Google Scholar
• Mittendorf EA, Lu B, Melisko M, et al. Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, Phase III clinical trial. Clin Cancer Res. 2019 Jul 15;25(14):4248–4254. doi: 10.1158/1078-0432.CCR-18-2867
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–821. doi: 10.1038/s41423-020-0488-6
   PubMed Web of Science ®Google Scholar
• Establishing the recommended biological dose for AE37 peptide vaccine in combination with Pembrolizumab that will enhance the tumor-specific immune response and demonstrate efficacy in patients with advanced triple-negative breast cancer. ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT04024800
   Google Scholar
• Gandhi S, Forsyth P, Opyrchal M, et al. 320 Phase IIa study of alpha-DC1 vaccine against HER2/HER3, chemokine modulation regimen and pembrolizumab in patients with asymptomatic brain metastasis from triple negative or HER2+ breast cancer. J Immunother Cancer [Internet]. 2020;8(Suppl 3). Available from: https://jitc.bmj.com/content/8/Suppl_3/A196.2
   Google Scholar
• Youssef M, Bao A, Phillips W, et al. LMAP-21 Preliminary clinical data in the phase 1/2a dose escalation trial of rhenium (186RE) obisbemeda (186RNL) in leptomeningeal metastases (LM): the respect-LM trial. Neurooncol Adv. 2023 Aug 4;5(Supplement_3):iii14–iii14. doi: 10.1093/noajnl/vdad070.052
   Google Scholar
• Paplomata E, O’regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014;6(4):154. doi: 10.1177/1758834014530023
   PubMed Web of Science ®Google Scholar
• Braal CL, Jongbloed EM, Wilting SM, et al. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and Abemaciclib: similarities and differences. Drugs. 2021 Feb 28;81(3):317–331. doi: 10.1007/s40265-020-01461-2
   PubMed Web of Science ®Google Scholar
• Jelovac D, Emens LA. HER2-directed therapy for metastatic breast cancer. Oncology (Williston Park) [Internet]. 2013;27(3):166–175.
   PubMed Web of Science ®Google Scholar
• Mortimer JE, Kruper L, Cianfrocca M, et al. Use of HER2-directed therapy in metastatic breast cancer and How community physicians collaborate to improve care. J Clin Med [Internet]. 2020;9(6):1984. Available from. doi: 10.3390/jcm9061984
   PubMed Web of Science ®Google Scholar
• Shah M, Nunes MR, Stearns V. CDK4/6 inhibitors: game changers in the management of hormone receptor–positive advanced breast cancer? Oncology (Williston Park) [Internet]. 2018;32(5):216–222.
   PubMed Web of Science ®Google Scholar
• Finn RS, Boer K, Bondarenko I, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat. 2020 Sep;183(2):419–428. doi: 10.1007/s10549-020-05755-7
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with Ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022 Mar 10;386(10):942–950. doi: 10.1056/NEJMoa2114663
   PubMed Web of Science ®Google Scholar
• Chen B, Dodge ME, Tang W, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 2009;5(2):100–107. doi: 10.1038/nchembio.137
   PubMed Web of Science ®Google Scholar
• Xu W, Lacerda L, Debeb BG, et al. The antihelmintic drug Pyrvinium pamoate targets aggressive breast cancer. PLoS One. 2013;8(8):e71508. doi: 10.1371/journal.pone.0071508
   PubMed Web of Science ®Google Scholar
• Schultz CW, Nevler A. Pyrvinium Pamoate: Past, Present, and Future as an Anti-Cancer Drug. Biomedicines. 2022;10(12):3249. doi: 10.3390/biomedicines10123249
   PubMed Web of Science ®Google Scholar
• Fatima I, I El A, Zacheaus C, et al. Abstract 1233: WNT inhibitor ICG-001 prevents visceral metastatic triple negative breast cancer in a chemo-resistant patient derived xenograft -PDX-model. Cancer Res. 2017;77(13_Supplement):1233. doi: 10.1158/1538-7445.AM2017-1233
   Google Scholar
• Lin Z, Lin Z, Zhao Y, et al. Auranofin and ICG-001 emerge synergistic anti-tumor effect on canine breast cancer by inducing apoptosis via mitochondrial pathway. Front Vet Sci [Internet]. 2021;8. Available from. doi: 10.3389/fvets.2021.772687
   Web of Science ®Google Scholar
• Espinoza I, Pochampally R, Xing F, et al. Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther. 2013;6:1249–1259. doi: 10.2147/OTT.S36162
   PubMed Web of Science ®Google Scholar
• Kar R, Jha NK, Jha SK, et al. A “NOTCH” deeper into the epithelial-to-mesenchymal transition (EMT) program in breast cancer. Genes (Basel). 2019;10(12):961. doi: 10.3390/genes10120961
   PubMed Web of Science ®Google Scholar
• JAK2 - my cancer genome [Internet]. [cited 2023 Nov 15]. Available from: https://www.mycancergenome.org/content/gene/jak2/
   Google Scholar
• Liu Q, Ai B, Kong X, et al. JAK2 expression is correlated with the molecular and clinical features of breast cancer as a favorable prognostic factor. Int Immunopharmacol. 2021;90:107186. doi: 10.1016/j.intimp.2020.107186
   PubMed Web of Science ®Google Scholar
• Mengie Ayele T, Tilahun Muche Z, Behaile Teklemariam A, et al. Role of JAK2/STAT3 signaling pathway in the Tumorigenesis, chemotherapy resistance, and treatment of solid tumors: a systemic review. J Inflamm Res. 2022;15:1349–1364. doi: 10.2147/JIR.S353489
   PubMed Web of Science ®Google Scholar
• Kim MS, Jeong J, Seo J, et al. Dysregulated JAK2 expression by TrkC promotes metastasis potential, and EMT program of metastatic breast cancer. Sci Rep. 2016;6(1):33899. doi: 10.1038/srep33899
   PubMedGoogle Scholar
• Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor, AZD1480, potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009;16(6):487. doi: 10.1016/j.ccr.2009.10.015
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Mosca A, Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol [Internet]. 2014;4. doi: 10.3389/fonc.2014.00064.
   PubMedGoogle Scholar
• Huang J, Chen L, Wu J, et al. Targeting the PI3K/AKT/mTOR Signaling pathway in the treatment of human diseases: current status, trends, and solutions. J Med Chem. 2022 Dec 22;65(24):16033–16061. doi: 10.1021/acs.jmedchem.2c01070
   PubMed Web of Science ®Google Scholar
• Cerma K, Piacentini F, Moscetti L, et al. Targeting PI3K/AKT/mTOR Pathway in breast cancer: from biology to clinical Challenges. Biomedicines. 2023;11(1):109. doi: 10.3390/biomedicines11010109
   PubMed Web of Science ®Google Scholar
• Yang J, Nie J, Ma X, et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1):1–28. doi: 10.1186/s12943-019-0954-x
   PubMedGoogle Scholar
• François-Martin H, Lardy-Cléaud A, Pistilli B, et al. Long-term results with everolimus in advanced hormone receptor positive breast cancer in a multicenter national real-world observational study. Cancers (Basel). 2023 Feb 13;15(4):1191. doi: 10.3390/cancers15041191
   PubMed Web of Science ®Google Scholar
• Schneble E, Jinga DC, Peoples G. Breast cancer Immunotherapy. Maedica (Bucur). 2015;10(2):185–191.
   PubMedGoogle Scholar
• Nakhjavani M, Shigdar S. Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer. Pharmacol Res. 2022;175:106019. doi: 10.1016/j.phrs.2021.106019
   PubMed Web of Science ®Google Scholar
• Planes-Laine G, Rochigneux P, Bertucci F, et al. PD-1/PD-L1 targeting in breast cancer: the first clinical evidences are emerging—A literature review. Cancers (Basel). 2019;11(7):1033. doi: 10.3390/cancers11071033
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Colak D, Tulbah A, et al. Towards targeting PD-1/PD-L1 axis in breast cancer, pre-clinical data. J Immunother Cancer. 2015;3(1):7. doi: 10.1186/2051-1426-3-S1-P7
   PubMedGoogle Scholar
• Li CJ, Lin LT, Hou MF, et al. PDL1/PD1 blockade in breast cancer: the immunotherapy era (review). Oncol Rep. 2021 Jan;45(1):5–12. doi: 10.3892/or.2020.7831
   PubMed Web of Science ®Google Scholar
• Yang T, Li W, Huang T, et al. Immunotherapy targeting PD-1/PD-L1 in early-stage triple-negative breast cancer. J Pers Med [Internet]. 2023;13(3):526. Available from. doi: 10.3390/jpm13030526
   PubMed Web of Science ®Google Scholar
• Jessurun CAC, Hulsbergen AFC, de Wit AE, et al. The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis. Neuro Oncol. 2021 Aug 2;23(8):1261–1272. doi: 10.1093/neuonc/noab046
   PubMed Web of Science ®Google Scholar
• Rohaan MW, Wilgenhof S, JBAG H. Adoptive cellular therapies: the current landscape. Virchows Arch. 2019 Apr;474(4):449–461. doi: 10.1007/s00428-018-2484-0
   PubMed Web of Science ®Google Scholar
• Patel U, Abernathy J, Savani BN, et al. CAR T cell therapy in solid tumors: a review of current clinical trials. EJHaem. 2021;3(Suppl 1):24–31. doi: 10.1002/jha2.356
   PubMedGoogle Scholar
• Ahmad U, Khan Z, Ualiyeva D, et al. Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review. Adv Cancer Biol Metastasis. 2022 Jul;4:100035.
   Google Scholar
• Wagner J, Wickman E, DeRenzo C, et al. CAR T cell therapy for solid tumors: bright future or Dark Reality? Mol Ther. 2020;28(11):2320–2339. doi: 10.1016/j.ymthe.2020.09.015
   PubMed Web of Science ®Google Scholar
• Tomasik J, Jasiński M, Basak GW. Next generations of CAR-T cells - new therapeutic opportunities in hematology? Front Immunol. 2022;13:1034707. doi: 10.3389/fimmu.2022.1034707
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010 Jul 1;28(19):3167–3175. doi: 10.1200/JCO.2009.26.7609
   PubMed Web of Science ®Google Scholar